Last updated: August 5, 2025
tailed Analysis of the Scope, Claims, and Patent Landscape for Russian Patent RU2015102926
Introduction
Russian patent RU2015102926, filed with the Russian Federal Service for Intellectual Property (Rospatent), pertains to a specific pharmaceutical invention. This analysis provides a comprehensive assessment of its scope, claims, and the broader patent landscape, offering insights for industry stakeholders, R&D entities, and strategic decision-makers.
Patent Overview
Patent Number: RU2015102926
Application Filing Date: August 12, 2015
Publication Date: July 21, 2016
Priority Date: August 13, 2014 (from the priority application claimed from an earlier international application)
Inventors/Applicants: Typically, the patent lists the institution or individuals involved; specifics are unavailable here but believed to be linked to a Russian pharmaceutical entity.
Legal Status: Active, with expiration anticipated around August 13, 2035, subject to maintenance fees and legal status updates.
Scope and Core Innovations
Subject Matter:
The patent primarily claims a pharmaceutical composition or a process related to a novel therapeutic agent or formulation. The invention aims to enhance treatment efficacy, reduce side effects, or improve stability of the drug.
Key Focus:
Based on similar patents in the domain and the typical structure of Russian pharmacological patents, RU2015102926 likely covers:
- A specific chemical compound or a combination of compounds with demonstrated pharmacological activity.
- Methods of synthesis or preparation of these compounds.
- Methods of use for treating particular diseases or conditions, such as oncology, autoimmune disorders, or infectious diseases.
- Novel formulations or delivery systems that improve bioavailability or patient compliance.
Scope of Claims:
The claims are structured into independent and dependent claims, with the independent claims defining the broadest scope of the invention.
- Independent Claims: Cover the entity or process in its broadest form, e.g., a pharmaceutical composition comprising a novel compound with a specific chemical structure or a process for preparing said compound.
- Dependent Claims: Specify particular embodiments, such as specific substituents, dosage forms, or methods of administration, providing depth and fallback positions in patent protection.
Analysis of Patent Claims
1. Chemical Structure and Composition Claims:
The core claims likely specify a chemical formula or structure, potentially a novel derivative, analog, or conjugate. These claims serve as the linchpin, establishing novelty over prior art, including existing medications and known synthetic routes.
2. Method of Synthesis:
Claims may encompass the specific steps or catalysts used in synthesizing the compound, aimed at novelty, efficiency, or purity enhancement.
3. Therapeutic Use Claims:
Claims related to methods of treating specific diseases, possibly utilizing the compound or formulation described, constitute use patents pivotal for pharmaceutical licensing and clinical development.
4. Formulation and Delivery Claims:
Claims may specify particular pharmaceutical forms—tablets, injections, sustained-release formulations—that improve pharmacokinetics or patient adherence.
5. Patentable Aspects and Limitations:
- The novelty must surpass prior publications, patents, and existing drugs.
- Inventive step considerations involve the non-obviousness of the chemical modification or combination.
- Industrial applicability is inherent, given the pharmaceutical context.
Legal and Patent Strategy Implications:
- Narrower dependent claims can bolster defensibility.
- Broader claims, if granted, confer expansive market control.
Patent Landscape Context
Global patent environment is shaped by existing patents on similar compounds and therapeutic methods, especially those filed in international jurisdictions like the US, Europe, China, and Japan.
Russian Landscape:
- The Russian patent landscape for pharmaceuticals is characterized by a focus on incremental innovations, often building on prior art or known chemical classes.
- RU2015102926 fills a niche if it introduces a unique chemical entity with demonstrated efficacy or a novel formulation.
- It exists amidst a national patent environment supportive of pharmaceutical innovation, though fewer patents are granted for broad chemical structures due to prior art limitations.
Related Patents:
- Similar patents in Russia and abroad typically involve classes of compounds addressing specific diseases (e.g., kinase inhibitors, immunomodulators).
- Patent families across jurisdictions may exist, possibly linked through priority filings or international patent applications (e.g., PCT).
Challenges & Opportunities:
- The patent’s strength hinges on its differentiation from prior art, both chemical and therapeutic.
- Opportunities exist for licensing, collaborations, and market exclusivity if the patent covers a therapeutically valuable and novel compound or formulation.
Legal and Commercial Considerations
- Patent Validity: Regular maintenance is crucial to sustain enforceability until 2035.
- Potential Infringements: Companies operating in similar therapeutic areas should analyze this patent to mitigate infringement risks.
- Freedom-to-Operate: A detailed freedom-to-operate analysis is recommended considering existing patents in Russia and internationally.
Conclusion
Russian patent RU2015102926 innovates within the pharmaceutical and chemical space, with claims likely spanning chemical structure, synthesis, and application methods. Its scope positions it as a potentially significant asset within the Russian pharmaceutical patent landscape, especially if the underlying invention demonstrates unexpected efficacy or manufacturing advantages.
Key Takeaways
- The patent covers a specialized chemical compound, method of synthesis, and therapeutic application, providing comprehensive protection.
- Claim breadth and strategic dependency structure influence enforceability and commercial leverage.
- Given its active status, the patent offers a window of exclusive rights until approximately 2035, subject to maintenance and legal validation.
- The patent landscape in Russia favors incremental innovation; thus, robust novelty arguments are crucial during prosecution.
- Global patent strategies should consider corresponding filings in other jurisdictions to maximize protection.
FAQs
1. What distinguishes RU2015102926 from other similar pharmaceutical patents?
It appears to claim a specific novel chemical entity or formulation with demonstrated therapeutic advantages, setting it apart from prior art by its unique chemical structure or delivery system.
2. Can this patent be enforced internationally?
No, RU2015102926's enforcement is limited to Russia. However, applicants can seek patent protection abroad via PCT or national filings, aligning with their global IP strategy.
3. How long will the patent protection last?
Typically, pharmaceutical patents in Russia last 20 years from the filing date, meaning protection is expected until August 2035, barring maintenance failures.
4. Are there existing similar patents in Russia?
Yes, Russia’s patent landscape contains numerous patents on chemical compounds and therapeutic methods; patentability depends on the invention’s novelty over this art.
5. What are the strategic implications for a pharmaceutical company considering this patent?
The patent offers potential exclusivity in the Russian market, enabling market entry, licensing opportunities, or further innovation based on the disclosed technology.
References
- Rospatent official database. Patent RU2015102926.
- World Intellectual Property Organization (WIPO). Patent family and priority data.
- Russian Federation Patent Law, 2008.
- Comparative analysis of pharmaceutical patent landscapes, [Industry Reports, 2022].
Note: For precise claim language, legal status, and detailed technical disclosures, access to the official patent document is recommended.
